Related Experiment Video

Updated: Jan 16, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.3K

Liposomal iron dramatic effect on chronic kidney disease pediatric anemia: a randomized clinical trial

Sahar Kamal Hegazy1, Mai Salah El-Din Koura2, Mohamed Shokry Elharoun3

  • 1Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Pediatric Research
|October 1, 2025
PubMed

Insights

Oral liposomal iron is a safe and effective treatment for pediatric anemia caused by chronic kidney disease (CKD). This oral option shows higher efficacy than intravenous iron dextran, improving patient compliance and outcomes.

Area of Science:

  • Pediatric Nephrology
  • Hematology
  • Pharmacology

Background:

  • Anemia in pediatric chronic kidney disease (CKD) significantly impacts quality of life, causing hypoxia and concentration issues.
  • Conventional treatments for pediatric CKD-induced anemia include various iron supplements.
  • Intravenous (IV) iron dextran is a common treatment, but concerns exist regarding side effects and patient compliance.

Purpose of the Study:

  • To evaluate the effectiveness and safety of oral liposomal iron compared to IV iron dextran for treating anemia in pediatric CKD patients.
  • To identify a safer, more effective, and patient-friendly treatment for pediatric CKD-associated anemia.

Main Methods:

  • A randomized, parallel study involving 60 pediatric CKD patients.
  • Group 1 received oral liposomal iron (30 mg/day) for 3 months.
  • Group 2 received IV iron dextran (50 mg thrice weekly) for 3 months.

Main Results:

  • Both groups showed no statistically significant differences in key hematological and biochemical markers (Hb, RBCs, Ferritin, etc.) after 3 months.
  • Oral liposomal iron demonstrated higher efficacy within its group, with significant improvements in Hb, RBCs, HCT, MCV, RDW-CV, Hepcidin, Ferritin, Iron, TIBC, and Transferrin levels.
  • No side effects were reported with oral liposomal iron during the study period.

Conclusions:

  • Oral liposomal iron is more effective than IV iron dextran for treating pediatric CKD-induced anemia.
  • Oral liposomal iron offers a safe, effective, and potentially more compliant alternative to traditional IV treatments for pediatric anemia.
  • This study supports oral liposomal iron as a preferred treatment option, addressing the need for improved pediatric anemia management in CKD.
Abstract

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.3K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214